ES2341922T3 - Composiciones medicas para el tratamiento intravesical de cancer de vejiga. - Google Patents

Composiciones medicas para el tratamiento intravesical de cancer de vejiga. Download PDF

Info

Publication number
ES2341922T3
ES2341922T3 ES09075067T ES09075067T ES2341922T3 ES 2341922 T3 ES2341922 T3 ES 2341922T3 ES 09075067 T ES09075067 T ES 09075067T ES 09075067 T ES09075067 T ES 09075067T ES 2341922 T3 ES2341922 T3 ES 2341922T3
Authority
ES
Spain
Prior art keywords
nqo1
cancer
activity
bladder
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09075067T
Other languages
English (en)
Spanish (es)
Inventor
Bastiaan Nuijen
Ernie Pfadenhauer
Jos F. Beijen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2341922T3 publication Critical patent/ES2341922T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES09075067T 2001-11-01 2002-11-01 Composiciones medicas para el tratamiento intravesical de cancer de vejiga. Expired - Lifetime ES2341922T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34444601P 2001-11-01 2001-11-01
US344446P 2001-11-01

Publications (1)

Publication Number Publication Date
ES2341922T3 true ES2341922T3 (es) 2010-06-29

Family

ID=23350584

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09075067T Expired - Lifetime ES2341922T3 (es) 2001-11-01 2002-11-01 Composiciones medicas para el tratamiento intravesical de cancer de vejiga.
ES06077149T Expired - Lifetime ES2384208T3 (es) 2001-11-01 2002-11-01 Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06077149T Expired - Lifetime ES2384208T3 (es) 2001-11-01 2002-11-01 Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga.

Country Status (12)

Country Link
US (6) US6894071B2 (cg-RX-API-DMAC7.html)
EP (3) EP2060259B1 (cg-RX-API-DMAC7.html)
JP (1) JP4317452B2 (cg-RX-API-DMAC7.html)
AT (2) ATE455545T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002350115A1 (cg-RX-API-DMAC7.html)
CA (2) CA2466148C (cg-RX-API-DMAC7.html)
CY (1) CY1111252T1 (cg-RX-API-DMAC7.html)
DE (2) DE60235214D1 (cg-RX-API-DMAC7.html)
DK (2) DK1864660T3 (cg-RX-API-DMAC7.html)
ES (2) ES2341922T3 (cg-RX-API-DMAC7.html)
PT (2) PT2060259E (cg-RX-API-DMAC7.html)
WO (1) WO2003037314A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
EP2060259B1 (en) * 2001-11-01 2010-01-20 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
AU2006230582A1 (en) * 2005-03-31 2006-10-05 Spectrum Pharmaceuticals, Inc. Indoloquinone tumor radiation sensitization
CA2653541C (en) 2005-06-06 2014-12-23 The University Of British Columbia Polymer-based serum albumin substitute
JP5457036B2 (ja) * 2006-02-09 2014-04-02 スペクトラム ファーマシューティカルズ インコーポレイテッド 腫瘍酵素レベルの決定を含む膀胱癌の処置
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
RU2480200C2 (ru) * 2007-03-13 2013-04-27 Спектрум Фармасьютикалз, Инк. Внутрипузырное введение апазиквона после трансуретральной резекции при лечении рака
RU2354386C1 (ru) * 2007-12-26 2009-05-10 ГУ Московская городская онкологическая больница №62 Департамента здравоохранения г. Москвы Способ профилактики рецидивов поверхностного рака мочевого пузыря
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
DE212011100034U1 (de) 2010-01-20 2012-07-04 Theracoat Ltd. Material zur Behandlung von inneren Hohlräumen
EP2542613A4 (en) 2010-03-01 2013-12-11 Univ British Columbia SUBSTITUTED HYPERBRANCHED POLYGLYCEROLS
TR201807363T4 (tr) * 2010-09-22 2018-06-21 Univ Texas Hedefleyici nqo1 i içeren kanser tedavi yöntemleri.
WO2013011504A1 (en) 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities
ES2596215T3 (es) 2011-10-24 2017-01-05 Asana Biosciences, Llc Ciclohexilaminas
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
AU2014365823B2 (en) 2013-12-16 2019-05-02 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods
CN104743887B (zh) * 2014-09-22 2016-03-23 巨石集团有限公司 一种玻璃纤维组合物及其玻璃纤维和复合材料
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
CN112220742A (zh) * 2019-07-15 2021-01-15 深圳艾欣达伟医药科技有限公司 稳定的ast-3424注射液制剂及制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
JPS54151134A (en) 1978-05-19 1979-11-28 Kureha Chem Ind Co Ltd Antitumorigenic agent
NL8001280A (nl) * 1980-03-04 1981-10-01 Philips Nv Lagedrukontladingslamp.
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
JPS60163621A (ja) 1984-02-02 1985-08-26 村上 俊文 紙製便座カバ−の製造方法
JPS60163821A (ja) 1984-02-03 1985-08-26 Tdk Corp フエライト粒子を含む薬剤用担体
JPS61189215A (ja) 1985-02-18 1986-08-22 Teijin Ltd 5−フルオロ−2′−デオキシウリジンエステル類の油状医薬組成物
DE3782938T2 (de) * 1986-04-17 1993-10-21 Everardus Arnoldus Oostveen Indochinon-verbindungen.
US4871542A (en) 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
EP0331635A3 (en) 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
EP0338679A3 (en) 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
FR2629584B1 (fr) 1988-03-31 1993-06-04 France Etat Armement Dispositif de stabilisation pour un projectile a faible moment d'inertie longitudinal tire a partir d'un tube raye
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
PT93772A (pt) 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
FI84874C (fi) 1989-11-02 1992-02-10 Valio Meijerien Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den.
US5237466A (en) 1989-11-02 1993-08-17 International Business Machines Corporation Method and apparatus for programmably controlling spindle synchronization and phase among disk drives in a storage subsystem
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
JP3598049B2 (ja) 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
EP0995447A1 (en) 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5405622A (en) 1993-12-22 1995-04-11 Vernice; Joseph Gamma radiation resistant lubricating gel
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
WO1997023456A1 (en) 1995-12-21 1997-07-03 British Technology Group Ltd. Indoloquinone derivatives as bioreductive agents
US5985312A (en) 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AU712953B2 (en) 1996-03-11 1999-11-18 Focal, Inc. Polymeric delivery of radionuclides and radiopharmaceuticals
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
JP2967734B2 (ja) * 1996-10-18 1999-10-25 日本電気株式会社 薄膜の形成方法
AU6876498A (en) 1997-04-03 1998-10-22 Point Biomedical Corporation Intravesical drug delivery system
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
WO1999012547A1 (en) * 1997-09-08 1999-03-18 Theramark Limited Treatment of inflammatory conditions
US6156744A (en) 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
EP0950418A2 (en) 1998-04-14 1999-10-20 Takeda Chemical Industries, Ltd. Composition for preventing or treating ischemic disease
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
AU739140B2 (en) 1998-05-05 2001-10-04 Astrazeneca Ab Mycobacterial inhibitors
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6087396A (en) 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
GB9827034D0 (en) 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
JP2000256182A (ja) 1999-03-03 2000-09-19 Kazuhiro Morimoto 抗菌製剤
EP1177439B1 (en) 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening for immunostimulatory dna functional modifiers
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US6887996B2 (en) 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
EP2060259B1 (en) 2001-11-01 2010-01-20 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
JP5184738B2 (ja) 2002-05-03 2013-04-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 修飾第vii因子の安定化された固体組成物
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1729012B (zh) 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
JP5457036B2 (ja) 2006-02-09 2014-04-02 スペクトラム ファーマシューティカルズ インコーポレイテッド 腫瘍酵素レベルの決定を含む膀胱癌の処置

Also Published As

Publication number Publication date
DE60238798D1 (de) 2011-02-10
US20080166402A1 (en) 2008-07-10
CA2466148C (en) 2013-01-08
CY1111252T1 (el) 2015-08-05
PT2060259E (pt) 2010-04-26
JP2005532986A (ja) 2005-11-04
CA2789114C (en) 2014-03-25
PT1864660E (pt) 2011-03-31
ES2384208T3 (es) 2012-07-02
CA2466148A1 (en) 2003-05-08
US20090076123A1 (en) 2009-03-19
EP2060259B1 (en) 2010-01-20
US20050215615A1 (en) 2005-09-29
WO2003037314A3 (en) 2003-10-16
ATE455545T1 (de) 2010-02-15
EP1439835A2 (en) 2004-07-28
US20120252861A1 (en) 2012-10-04
ATE493126T1 (de) 2011-01-15
EP2060259A1 (en) 2009-05-20
US8648108B2 (en) 2014-02-11
EP1864660A3 (en) 2008-04-23
US6894071B2 (en) 2005-05-17
EP1864660A2 (en) 2007-12-12
US20070010570A1 (en) 2007-01-11
AU2002350115A1 (en) 2003-05-12
US20030133954A1 (en) 2003-07-17
WO2003037314A2 (en) 2003-05-08
US7977369B2 (en) 2011-07-12
CA2789114A1 (en) 2003-05-08
DK2060259T3 (da) 2010-05-17
DE60235214D1 (de) 2010-03-11
EP1864660B1 (en) 2010-12-29
HK1132181A1 (en) 2010-02-19
JP4317452B2 (ja) 2009-08-19
DK1864660T3 (da) 2011-02-21

Similar Documents

Publication Publication Date Title
US8648108B2 (en) Medical compositions for intravesical treatment of bladder cancer
Choudry et al. A novel strategy for NQO1 (NAD (P) H: quinone oxidoreductase, EC 1.6. 99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
Anabousi et al. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer
Sudimack et al. A novel pH-sensitive liposome formulation containing oleyl alcohol
Bochot et al. Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides
AU2002305094C1 (en) Liposome composition for improved intracellular delivery of a therapeutic agent
Boyer et al. Lysosomes, lysosomal enzymes, and cancer
US8236329B2 (en) Micelle encapsulation of therapeutic agents
US9295666B2 (en) Bladder cancer treatment and methods
ES2327313T3 (es) Pentamidina para el tratamiento del cancer.
Sharma et al. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers
ES3009563T3 (en) Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels
HK1132181B (en) Medical compositions for intravesical treatment of bladder cancer
US20110288472A1 (en) Bladder cancer treatment and methods
US20130164379A1 (en) Nanoparticle micelle coated compositions
Richard et al. Delivery of ROS Generating Anthraquinones Using Reduction‐Responsive Peptide‐Based Nanoparticles
HK1109875A1 (en) Medical compositions for intravesical treatment of bladder cancer
HK1109875B (en) Medical compositions for intravesical treatment of bladder cancer
Bölükbaş Development of novel nanoparticle-based therapeutics for treatment of lung cancer
Liao et al. Liposomal delivery of α-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis
Gosselin Polyethylenimine and liposome-based non-viral vectors for gene delivery